 | |||||||
| technology | |||||||
| NEWS | |||||||
Darolutamide Offers Unique QOL Advantage Among AR Inhibitors in mHSPC While androgen receptor (AR) inhibitors have long been a cornerstone in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), the ARANOTE trial (NCT04736199) sets darolutamide (Nubeqa) apart from the rest, especially in terms of its ...
| |||||||
| See more results | Edit this alert | |||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment